Australian Government Accused of Misusing Funds to Combat E-Cigarettes

Sep.09.2022
Australian Government Accused of Misusing Funds to Combat E-Cigarettes
CAPHRA Coordinator Nancy Loucas criticizes Australian government's anti-vaping campaign as a misuse of public funds.

Nancy Loucas, the executive coordinator of the Asia Pacific Advocates for Tobacco Harm Reduction (CAPHRA), has expressed that the crackdown on e-cigarette retailers in Australia constitutes a serious misuse of public funds, which should be directed towards improving the country's healthcare system.


Before she issued her statement, the government of New South Wales in Australia intensified its warnings to compliant retailers about the risks associated with e-cigarette products. They also continue to back a controversial joint "education campaign" with the Department of Education on the issue of e-cigarettes.


The centerpiece of the event is the "Get the Facts" - Vaping Toolkit aimed at teachers, parents, and adolescent students. CAPHRA stated that despite Deputy Chief Health Officer Dr. Marianne Gale's assurance that the website does not contain "evidence-based resources and educational materials," it should be taken down while its many statements are independently verified.


These claims about electronic cigarettes are either completely exaggerated or, in the worst case scenario, have no scientific basis. The Australian public, regardless of age, needs to have complete confidence in any health statements on government websites. Unfortunately, this campaign is far from factual. Instead, it is filled with blatant lies," said Ms. Lucas.


In a statement that has angered advocates for tobacco harm reduction (THR) throughout the entire Asia-Pacific region, Dr. Gale claimed, "Many people believe that e-cigarettes are either completely harmless or less harmful than traditional cigarettes.


In a recent situation, an Australian chief health officer has been actively informing the public that the harm of vaping is not less than smoking. However, international research strongly refutes this claim. Despite providing no evidence to support her statement, the Australian public continues to receive such costly yet worthless advice. This is a complete embarrassment," she said.


According to CAPHRA, Australians who want to know the truth about vaping should look to New Zealand. Adults can legally use nicotine e-cigarettes there under regulations targeting retailers and manufacturers in 2020. Smokers looking to quit do not need to obtain a prescription from a doctor, unlike in Australia.


Asking doctors to prescribe cigarettes has left 2.3 million smokers in Australia disappointed, not to mention the approximately 20,000 Australians who die each year from smoking-related illnesses. While Australia's overall smoking rate has remained stagnant over the past decade, New Zealand has seen a 50% decrease in its smoking rate, largely due to the availability of legally sanctioned, less harmful alternatives for smokers, according to Ms. Lucas.


CAPHRA has pointed out that the headline of the New Zealand Ministry of Health's "Vaping facts" website states that "vaping is less harmful than smoking".


New Zealand is engaging in a positive dialogue with the public with the goal of achieving a smoke-free nation by 2025, with a smoking rate of 5% or less. In contrast, health leaders in Australia are continuing to ban adults from entering retail stores while using significant public resources to deter the use of e-cigarettes.


Australia's healthcare system is failing miserably. The persistent threats and lies surrounding e-cigarettes will make it almost impossible to achieve the country's goal of reducing smoking rates by 10% in the short term. They need a new strategy to eradicate tobacco, as the current one clearly isn't working," said Nancy Lucas.


CAPHRA, an advocacy group, has amassed almost 15,000 endorsement letters and is urging those who have quit smoking through the use of nicotine-free alternatives to share their stories on www.righttovape.org.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the opinion of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article’s content. The compilation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
Gallery | InterTabac 2026 Opens as VAPORESSO, SKE, GREENTANK, GEEK BAR and Other Brands Take the Floor
InterTabac 2026 opened in Dortmund, Germany, on September 15 alongside NUBIZ and InterSupply. According to the latest figures released by the organizer, the three trade shows bring together around 750 exhibitors from 64 countries. On site, 2Firsts observed vaping and related brands including VAPORESSO, DOJO, SKE, GREENTANK, GEEK BAR, HQD and ELUX.
Special Report
Sep.15
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives